Coronary artery stents: appropriate use of adjunctive pharmacotherapy to prevent stent thrombosis

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials Science

Background:

• Metallic stents were first used in coronary arteries in 1986 to prevent vessel occlusion and restenosis after angioplasty.
• Initial use was associated with high rates of thrombotic stent closure, occurring weeks after implantation.
• Early antithrombotic drug trials reduced thrombosis but increased bleeding complications and hospitalization.

Purpose of the Study:

• To review the evolution of stent implantation techniques and antithrombotic strategies.
• To highlight advancements in reducing stent thrombosis and improving patient outcomes.
• To discuss the impact of improved deployment and antiplatelet therapy.

Main Methods:

• Review of historical data and clinical trials on coronary stent implantation.
• Analysis of the impact of anticoagulation and antithrombotic drug regimens.
• Evaluation of the role of intravascular ultrasound and high-pressure ballooning in stent deployment.
• Assessment of novel antiplatelet agents and stent designs.

Main Results:

• Early stent implantation faced challenges with thrombotic closure, necessitating extensive drug trials.
• Improved stent deployment techniques, including intravascular ultrasound guidance and high-pressure inflation, significantly reduced thrombosis.
• The combination of optimal stent deployment and potent antiplatelet therapy, including aspirin and glycoprotein IIb/IIIa inhibitors, has become standard practice.
• Newer stent designs and targeted therapies are under ongoing evaluation.

Conclusions:

• Coronary stent implantation has evolved significantly since its inception.
• Optimal stent deployment and advanced antiplatelet strategies are crucial for minimizing thrombotic complications.
• Continued research into novel stent designs and pharmacotherapies promises further improvements in cardiovascular interventions.